Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

November 3, 2022

NASDAQ US Health Care Biotechnology earnings 81 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us today. Robert Blum, our President and Chief Executive Officer, will kick things off with a short review of the quarter and what's happened recently; Fady Malik, EVP of R&D, will share updates on omecamtiv mecarbil and aficamten; Andrew Callos, EVP and Chief Commercial Officer, will go over commercialization planning work for omecamtiv mecarbil along with our specialty cardiology franchise strategy for aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will give an update on reldesemtiv; Robert Wong, VP and Chief Accounting Officer, will walk through a financial overview of the quarter just ended; and Ching Jaw, SVP and Chief Financial Officer, will talk about our financial outlook and corporate development. Then, to wrap up, Robert Blum will offer closing remarks and go over the key milestones we expect ahead. Please be aware that parts of what we discuss next, including answers to your questions, include statements about future events and performance instead of historical facts, and these are forward-looking statements. What actually happens could differ materially from what those forward-looking statements project. Details about factors that might make our actual results differ materially from those in these forward-looking statements can be found in our SEC filings, including our current report on our third quarter 2022 financial results filed today on Form 8-K; we take on no obligation to update any forward-looking statements after this call. And now, I'll hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I appreciate everyone being on today's call. We achieved solid progress during Q3, and as we moved toward the close of the year, our financial standing was strong, with meaningful strides made throughout the organization and across our programs. The standout item during that quarter was that we moved forward with planning for a possible launch of omecamtiv mecarbil, contingent on FDA approval, which could come next year. In the past few months, we kept up constructive dialogue with FDA while it proceeds with its review of our NDA, and we anticipate the late cycle review happening later this quarter, ahead of the Advisory Committee meeting. Working productively with FDA is a top priority. Because of that, our teams have concentrated heavily on preparations that will carry on over the coming several weeks as we get ready to take part in that significant meeting. We also pushed ahead with regulatory groundwork for omecamtiv mecarbil beyond the United States. We're still on schedule to file a marketing authorization application with the European Medicines Agency prior to the close of the year, consistent with our go-to Europe strategy. Regarding aficamten, we kept SEQUOIA-HCM running, finished patient screening in Cohort 4 of REDWOOD-HCM, and moved forward with start-up work for the second Phase 3 trial of aficamten as monotherapy — a Phase 3 trial where we anticipate activating sites by year-end, with enrollment starting next year. During that quarter, we also presented findings from two analyses of the open-label extension trial of aficamten, both of which deepen our insight into the possible advantages of longer-term treatment with aficamten and, in particular, reinforce our reasoning for moving the program forward to expand on aficamten's potential as a monotherapy. On reldesemtiv, we were glad that the DMC, or data monitoring committee, advised that COURAGE-ALS keep going after examining unblinded data from the trial. As you're aware, our dedication to this unrelenting disease goes back a long way, and it stays critically important to us to carry out rigorous clinical research so we can fully grasp the potential efficacy and safety of reldesemtiv. Patient enrollment in COURAGE-ALS is ongoing as that trial moves toward its second interim analysis, which we expect next year. It's an exciting and likewise busy period for everyone here at Cytokinetics, yet as you'll hear today, we're in a good position as we keep transforming and maturing our company. We look forward eagerly to next month's advisory committee, our PDUFA date in February, and many other corporate milestones spanning our early-stage and later-stage pipeline, as you're about to hear more about. With that, I'll hand the call to Fady.

Fady Malik

executive
#3

Appreciate that, Robert. As Robert pointed out, one of the biggest things on our plate these last several months has been getting ready for the advisory committee meeting on omecamtiv mecarbil that's coming up. Members of our team have run mock panels with outside experts, gone through our presentations in rehearsal, and gotten ready for the kinds of questions that could come up at the AdCom. On top of that, we're putting together supporting materials meant to tackle subjects that might be raised. Just to remind everyone, we still don't have the agenda for the meeting or the particular questions FDA intends to pose, though our belief is that the advisory committee will be asked to weigh in on matters concerning substantial evidence of benefit, benefit/risk, and dosing. Even with all this hard work and the commitment our team has shown, we're confident we'll be thoroughly prepared for the advisory committee. Before our late-cycle review meeting with the < > that we expect later this quarter, we've kept up our conversations regarding the dosing of omecamtiv mecarbil, its benefit-risk profile and heart failure patients, and the benefit-risk profile and heart failure patients at elevated risk for death and heart failure events, where adding omecamtiv mecarbil to the standard of care seems to deliver a greater benefit; we've also talked with FDA about possibly using a test that measures plasma concentrations of omecamtiv mecarbil to guide dosing. In GALACTIC-HF, we used an assay to evaluate plasma concentrations of omecamtiv mecarbil for guiding dose titration, and together with FDA we're discussing how such a test might potentially be implemented in clinical practice in settings where omecamtiv mecarbil could win approval. Now switching to Europe. As Robert noted, we took part recently in productive meetings with assigned rapid tours as we prepare for the MAA filing we expect, which we plan to submit by the end of the year. Additional regulatory developments should also come in other geographies, and we'll share more updates as they happen. On aficamten, we've kept making headway with its development program as well. SEQUOIA-HCM is enrolling patients around the world, and we currently have roughly 70 sites operational across the US, Europe, Israel and China, most of which our team went to see in person over recent weeks to help with activation and patient enrollment. Our expectation is that the majority, if not all, of the clinical trial sites will be actively enrolling patients during this fourth quarter. Right now the trial remains on track to finish enrollment in the first half of 2023, which ought to allow top-line results to become available in the second half of next year. Moving to Cohort 4 of REDWOOD-HCM, we've finished screening for patients who have non-obstructive HCM, and patient entry into the study ought to wrap up shortly. We look forward to sharing results from Cohort 4 in the first half of next year, which could position us to move ahead into a pivotal Phase 3 clinical trial in nonobstructive HCM in the second half of 2023. Last, we've continued preparations and study start-up work for our second Phase 3 clinical trial of afIcamten in obstructive HCM. Just to remind everyone, this extra study is meant to assess how safe and effective aficamten is on its own, versus metoprolol, which is a widely used beta blocker among patients dealing with symptomatic obstructive HCM. Hopefully, this study gives us a clearer picture of how aficamten might fit in relative to the treatments currently considered standard of care. The protocol is now locked down, sites are getting prepared, and our expectation is that sites will be ready to go by the close of 2022, with enrollment kicking off in early 2023. This quarter, we shared results from two analyses drawn from the open-label extension study of aficamten. Before walking through those findings, I want to touch on what this study is called. Up to this point, we've called it REDWOOD-HCM OLE, but we've just changed the name to FOREST-HCM, which stands for five-year open-label research evaluation of sustained treatment with aficamten and HCM. That new name, FOREST-HCM, better captures the fact that patients are included not just from REDWOOD-HCM, but from SEQUOIA-HCM and other upcoming aficamten trials, since it will be open to every patient who finishes treatment across all aficamten clinical trials. Nothing in the trial's protocol was altered because of this renaming. Now, on to what those recently presented analyses showed. The first one, presented at the inaugural meeting of the hypertrophic cardiomyopathy society, looked at reduction or withdrawal of background therapy among patients on aficamten; out of the 20 patients who made it through week 12 of treatment and qualified for this analysis, 17 successfully reduced or withdrew background therapy, defined as cutting at least one medication's dose by one step to under 50% of what it was at baseline. Ten patients stopped at least one medication entirely, and five came off all standard-of-care therapies. Reduction or withdrawal of background therapy failed in three patients, who went back on a beta blocker because symptoms returned or their left ventricular outflow tract gradient rose. Among aficamten-treated patients who did successfully reduce or withdraw background therapies, LVOT gradients, NYHA class and biomarkers stayed comparable to those who continued on other background therapies; these findings back up the rationale for now exploring aficamten as monotherapy, potentially to further flesh out its next-in-class profile. The second analysis, presented at the Heart Failure Society of America meeting, looked at patients' self-reported health status and found that by week 12, patients on aficamten were already seeing substantial and significant symptom improvements, based on the change in KCCQ score, which suggests aficamten is tied not just to better cardiac function, but also to less symptomatic burden and improved quality of life. Cytokinetics' footprint at medical conferences such as HFSA and HCM Society has strengthened over the years and now includes not only our presentations and posters, but our exhibit booth, sponsored symposia, backing for independent medical education, and other medical affairs efforts. Such gatherings give us chances to engage with top-tier investigators and care teams, putting the strength of our research and studies on display, while also helping meet the education goals of health professionals. The fact that our footprint at these meetings keeps widening shows how essential they have become, especially as we move toward a possible nod and commercial debut for omecamtiv mecarbil, which backs up our franchise plan, along with the prospective future clearance and introduction of aficamten. In step with that work, we keep building out both our home office and regional medical affairs group, and we have brought people into crucial posts across the medical director, medical science, and medical communications areas. In the course of the quarter, we likewise kicked off efforts with a vendor for medical information, laying groundwork for our medical contact center. Having said that, I will pass things to Andrew so he can walk you through where we stand on commercial preparations tied to the specialty cardiology franchise approach we intend to pursue.

Andrew Callos

executive
#4

Appreciate that, Fady. During Q3, the work we're doing to get commercially ready keeps moving us toward the goal of an omecamtiv mecarbil launch, should approval come through. That readiness progress involves prioritizing market access, with a strong push on payer engagement that never stops, since we're still sitting down with the biggest national commercial and Medicare payers. Talks have also been happening with important regional payers about the value proposition and the clinical evidence behind omecamtiv mecarbil, and along the way we kept up our presence at payer conferences, plus medical conferences, backed by our medical affairs and ATOR colleagues. To help people better understand how diminished contractility plays a role in heart failure, we were glad to formally roll out a disease state education initiative named The Heart of Contractility this quarter. This initiative is meant to raise awareness within the ATP community about worsening heart failure and the lingering burden those patients carry, while also teaching professionals why cardiac contractility matters and how it could be viewed as part of the pathogenesis of heart failure. Right now the initiative features a website, digital advertising, signage placed at medical conferences, and other components. On top of that, we kept pushing forward the strategic design and build-out of our patient support and services hub — a key piece that puts patient centricity right at the center of our commercial approach for omecamtiv mecarbil. Now shifting to distribution and supply for omecamtiv mecarbil: we've wrapped up our third-party logistics agreement, moved several wholesale agreements ahead, and completed a strategic sourcing assessment of contract manufacturing organizations for both drug substance and drug product, and did so successfully. Just like in earlier quarters, our team kept expanding; we kicked off hiring the last wave of sales force leaders, and close to 90% are now in place, against our target of having every one of them aboard by January. For that initial wave of sales leaders, and for the people we recently started recruiting, the response has been phenomenal — more than 500 applications came in for only the first 12 positions, and the top-tier candidates bring outstanding backgrounds, averaging 14 years in cardiovascular experience, 13 years of leadership experience, and 22 years in pharma. I'm confident a strong team is being built, and I expect we'll fill our roles with equally high-caliber talent. If approval is granted, we'll start hiring, onboarding, and training in the Shell Fresh, < > — more specifically, within one week of approval, our plan is to kick off non-personal and digital promotions. At that point, sales leaders will be out in the field, the medical affairs team will keep engaging with HCPs, and we also anticipate launching our product booths along with related education at ACC next year. Past all of this, plenty of other pieces of our launch strategy are advancing, quietly behind the scenes, as we get ready for what could be a transformational milestone for our company. Last, on the aficamten front, throughout the quarter we kept working on our U.S. go-to-market strategy. Under our trail and U.S. marketing lead, initial plans should be ready by the end of the year. If we take our plan for being commercially ready and combine it with the launch preparations for omecamtiv mecarbil as well as aficamten, that could give us important synergies, possible benefits, and cross-training opportunities for everyone who is involved. So with that said, I'll hand the call over to Stuart so he can give an update on reldesemtiv.

Stuart Kupfer

executive
#5

Appreciate it, Andrew. Turning to reldesemtiv in Q3, we kept moving forward with enrolling patients in COURAGE-ALS. To date, we've got over 300 patients signed up, and almost all of the more than 80 sites worldwide are now activated, with strong enrollment across three key regions: the U.S., Europe, and Australia. Things are going nicely on the enrollment front. We expect to wrap up enrollment during the first half of 2023. Not long ago, we shared that COURAGE-ALS would continue after the initial interim analysis performed by the Data Monitoring Committee, which looked at unblinded trial data; that analysis evaluated futility and was set off 12 weeks after roughly one-third of the planned patient count had been randomized. A second interim analysis should happen in the first half of 2023, and it will likewise evaluate futility, while also permitting a fixed bump in overall enrollment if needed to boost the trial's statistical power. Meanwhile, the Open-Label Extension, or OLE, for COURAGE-ALS is up and running for patients finishing COURAGE-ALS, and right now we're putting the finishing touches on plans to launch a managed access program in Q4 of this year. As a reminder, that program will be offered to patients who finished any of our earlier ALS studies, such as FORTITUDE-ALS, the Phase 2 study of reldesemtiv, and VITALITY-ALS, the Phase 3 study of tirasemtiv. People with ALS urgently need new treatments, even with the advances and headway made in the treatment landscape, among them the recent approval of sodium phenylbutyrate plus taurursodiol for ALS patients. That approval isn't just welcome news for patients — it also shows flexibility from the FDA in speeding up the path to approval. ALS patients face a tremendous disease burden, and we stay committed to rigorously evaluating reldesemtiv for what it might offer in ALS; and with that, I'll hand things over to Robert Wong.

Robert Wong

executive
#6

Appreciate that, Stuart. We closed out the third quarter holding roughly $896 million in cash and investments. During Q3 2022, the bulk of our revenue came from Apellis as part of co-funding COURAGE-ALS. R&D expenses for the third quarter of 2022 rose to $62.7 million, compared with $48.4 million in the same period of 2021, driven mainly by greater spending on clinical development work for COURAGE-ALS and SEQUOIA-HCM, along with our other cardiac muscle inhibitor and early research programs. G&A expenses for the third quarter of 2022 totaled $48.2 million, an increase from $26.2 million in Q3 2021, largely because of higher outside service costs tied to preparing for a possible commercial launch of omecamtiv mecarbil, plus a rise in personnel-related expenses that includes stock-based compensation. In the quarter, we recorded a $22.2 million loss connected to the conversion and partial settlement of our 2026 convertible notes. Ching will now walk through our financial outlook and corporate development strategy.

Ching Jaw

executive
#7

Thank you, Robert. We closed out the third quarter sitting in a solid financial spot, holding roughly $896 million of cash on the balance sheet. That figure takes in about $523 million of net proceeds that came from an offering of 3.5% convertible senior notes. Those notes carry a 30% conversion premium NR and come due in 2027. Tied to that deal, we bought back, via privately negotiated transactions, approximately $117 million in aggregate principal amount of our outstanding 2026 notes. On top of that, we finished unwinding the cap call instrument that we had entered into back in 2019 alongside that year's 4% convertible senior note offering. That transaction closed in October of this year and brought in roughly $26 million of extra cash. Into Cytokinetics, we sit in a strong cash position even though we expect our burn rate could rise next year as omecamtiv mecarbil potentially gets commercialized. So that we can prudently manage our spend as we near potential commercialization, we have guided a majority of launch-related expenses to post PDUFA date. Beyond that, we can tap additional capital by way of our deal with Royalty Pharma, assuming we satisfy the conditions to disbursement. By using our expense-gating strategy together with the option of drawing down that capital when needed, we feel confident about our cash runway. With that, I'll hand the call back to Robert Blum.

Robert Blum

executive
#8

I appreciate that, Ching. As we get ready to wrap up 2022 — a period marked by advancement throughout our pipeline — we're stepping into perhaps a fresh chapter for Cytokinetics. Our organization has grown up when it comes to our people and what we're able to do, and there are milestones ahead in the near term that could potentially be transformative. We're picking up speed and making more headway so that we're prepared for what we're hopeful will be an even more brilliant future; and while we look ahead toward possibly bringing our first medicine to market, with a second one trailing that by just a handful of years, we stay committed to pushing forward our earlier-stage pipeline. Before this year is done, we intend to kick off a Phase 1 trial of CK-136, which is yet another new cardiac muscle activator, aiming to move onward into potentially Phase 2 studies across specialty cardiovascular indications that would complement the ones for omecamtiv mecarbil — expect more details about this thrilling pipeline expansion from us shortly. On the business development front, talks are ongoing with prospective partners about possibly co-commercializing omecamtiv mecarbil across Europe and Japan. When it comes to Japan, we're additionally seeking to bundle the rights for both omecamtiv mecarbil and aficamten. What we've learned through progress with regulatory authorities has shaped these conversations, and at the same time, we're getting clearer on what we ourselves want from a deal, and we anticipate sharing additional updates. Then last but not least, during the quarter we marked the launch of our East Coast office, situated outside Philadelphia, where a number of staff from our commercial, our medical affairs, and our supply chain groups will be located. This new office stands as another sign of how we've matured and our optimism, and it makes me happy to witness the wins we're notching and the teams we're bringing on board now on both sides of the country; given all that, I'd like to go over the milestones coming up for us. When it comes to omecamtiv mecarbil, we anticipate taking part in an advisory committee meeting on December 13, 2022, to review the NDA for omecamtiv mecarbil. We likewise anticipate launching omecamtiv mecarbil in the US, assuming FDA approval comes through in Q1 2023; and we anticipate filing a marketing authorization application for omecamtiv mecarbil with the European Medicines Agency before 2022 comes to a close. Regarding aficamten, we anticipate carrying on with enrollment of obstructive HCM patients in SEQUOIA-HCM across the first half of 2023, with results anticipated during the second half of 2023. And we anticipate finishing enrollment of non-obstructive HCM patients in Cohort 4 of REDWOOD-HCM, with data anticipated in the first half of 2023, and we anticipate kicking off a second Phase 3 clinical trial of aficamten in obstructive HCM in Q4 2022. As for CK136, we anticipate starting a Phase 1 study in Q4 2022; and regarding reldesemtiv, we anticipate moving through the conduct of the second interim analysis for COURAGE-ALS in the first half of 2023 and carrying on with enrollment of ALS patients in COURAGE-ALS, which is anticipated to finish enrollment in the first half of 2023; and when it comes to our ongoing research, we anticipate pushing forward new muscle-directed compounds in addition to carrying out IND-enabling studies for one to two possible drug candidates. Operator, having said that, we're ready to begin taking questions on the line now, please.

Analyst

analyst
#9

Hello, I'm Iris, filling in for Akash. We appreciate you answering our questions. If I could, I have a couple. The first concerns the non-obstructive HCM trial. What is your internal threshold for success in this study when it comes to market reduction? Do you have to demonstrate marker reduction comparable to your OHCM trial? And what data would aficamten need to demonstrate to indicate that aficamten is distinctly differentiated from < > and HCM patients? My second question involves the IRA. So, since this has now turned into — it's evidence that orphan disease drugs will qualify for drug negotiation when the label is broadened. So, will you rethink your approach in this area when you seek to broaden aficamten initiation for indications past just OHCM? Thank you.

Robert Blum

executive
#10

So, we'll take your second question first, and I'll have Fady address the first. Concerning the Inflation Reduction Act and what it might mean for aficamten, I don't anticipate any consequences that would shift our strategy regarding aficamten. We remain concentrated on developing aficamten for obstructive and non-obstructive HCM, and we don't anticipate that this new regulation will cause us to change course. Regarding your first question, we do believe we've already observed sufficient evidence in Cohort 4 to give us confidence in a potential next-in-class profile for aficamten in non-obstructive HCM. We already believe we've seen enough in the open-label cohort to guide our desire to move forward to end of Phase 2 interactions and the launch of a Phase 3 study in 2023. On the specifics, I'll ask Fady perhaps to address what we regard as the bar here, but please realize we likely won't be as precise given that this is an open-label study, it is still ongoing and being conducted, and we don't want to do anything that could jeopardize the presentation of those data once those data are final.

Fady Malik

executive
#11

Yeah, what I'd say is that I don't think I'll offer any specific quantitative figures. What we were looking for was consistency across the various domains we studied with aficamten and HCM. That means consistent improvements in NYHA class, in KCCQ, in biomarkers, and in echocardiographic measures of response. So it isn't really a particular number — it's more about a consistent effect across a range of domains, some of which would form part of the efficacy outcomes in a Phase 3 trial. And the second part of your question concerned how aficamten would be differentiated in NHCM. I think every reason we believe it will be differentiated in OHCM also holds for NHCM, and that relates to rapid dose titration, absence of drug-drug interactions, reversibility of effect, and some of the other features we've outlined before. So I think those pharmacokinetic and pharmacodynamic properties are relevant to both OHCM and HCM.

Analyst

analyst
#12

This is great. Thank you.

Robert Blum

executive
#13

Hello Carter.

Carter Gould

analyst
#14

Hi Robert. Thanks a lot for fielding this one. Good afternoon, everyone. This may be somewhat of a follow-up to what was asked earlier. I'm certain you're aware of Bristol's Phase 3 design in the non-obstructive segment regarding the use of the dual endpoint. Could you briefly say whether that aligns with your thinking on a possible Phase 3, or any takeaways from reviewing that design and perhaps some of your discussions with KOLs and/or FDA? Then on omecamtiv, just quickly, is there any shift in your planning as you get somewhat nearer to the AdCom concerning points of focus or key topics? Thank you.

Robert Blum

executive
#15

Yes. Let me address your latter question first, and then I'll have Fady share our thinking about the BMS-reported study on CAMZYOS. As for the advisory committee that's coming up, we've been in touch with the FDA quite a bit lately, and we're getting a clearer sense of which topics might come up for discussion at the AdCom. That said, the late cycle meeting hasn't happened yet, and we don't have an official agenda or official topics. Still, because we've been talking with the FDA so regularly over the course of many months, some things are coming into sharper focus. That's why we put specific language about these matters into the press release. As you noticed, the press release noted our anticipation of inquiries regarding benefit-risk as it pertains to dosing and safety. Those are things we still anticipate will influence what the label could look like and the way it ends up being written; there could also be additional items. Going into details isn't something we can do during this call, since doing so wouldn't be suitable. Still, my sense is that nothing here will catch us off guard, because the conversation we've had with FDA has been highly open and productive. We're going into this believing that the Phase 3 trial will turn out favorably. This is a pivotal study — one that received extensive discussion with the FDA both prior to and following its execution. Although the results overall were favorable, we're also aware that certain pre-specified subgroups show a more substantial effect. Given that, it seems fair to anticipate some discussion around benefit-risk and the populations where the effect might be seen and be stronger. At the end of the day, that's really the right thing for the advisers to weigh in on, so I hope that addresses what you were asking. To circle back to what you asked initially, I'd like Fady to weigh in on how we see the BMS study's design and what implications that could hold for us.

Fady Malik

executive
#16

Hey Carter. My view is that when you're putting together any of these trials, you have to think about which endpoints you'll use, so that what gets reported actually tells you something meaningful about how patients feel and how they function. In the same way, as I've mentioned on earlier calls, every endpoint we looked at in oHCM carries over to nHCM — that means NYHA class, KCCQ, exercise performance. So when I look at how the Phase 3 study of aficamten is structured, I believe a lot of those elements are in there. And you'd anticipate that any clinical trial designed for this patient group would build in endpoints of that type. It's still a bit soon for me to get into the details of what we ourselves are thinking, and we intend to share that later on; but broadly speaking, the kinds of endpoints they're using are obviously meaningful ones.

Robert Blum

executive
#17

Also, perhaps I should mention, the trends we’re observing didn’t really catch us off guard—they line up with what we had anticipated.

Robert Blum

executive
#18

Hi there, Yasmeen.

Yasmeen Rahimi

analyst
#19

Hey Robert, and hello to everyone on the team. I really appreciate you all fielding my questions, and congratulations on the recent updates. So, for my first one: we're all eager to find out what the mavacamten VALOR results show. That said, could you remind us whether that patient group is already covered within SEQUOIA, or would a separate but comparable trial be necessary before you could submit a filing or make the therapy available to patients for the purpose of decreasing septal ablation? Would you mind giving us your thoughts on how you plan to handle that? Then my second question: you mentioned that screening has wrapped up among the non-obstructive HCM group. So does your rate of screen failures in the non-obstructive group look different compared with the obstructive group? If it does, what does that reveal regarding these two distinct groups? And once more, thank you for answering my questions.

Robert Blum

executive
#20

Of course. Let me make sure I understand — you referred to anticipating the VALOR results; those results are already out. What you probably intended was waiting to see if the FDA will broaden the label…

Yasmeen Rahimi

analyst
#21

That is correct, yes.

Robert Blum

executive
#22

To mirror what VALOR showed us. All right. Indeed, a submission was made for the supplemental NDA. Indeed, watching how that plays out will be intriguing. Based on what VALOR revealed, I would describe it as informative yet possibly not taking us much further than what we believed EXPLORER had already established; and with VALOR, as you are aware, they managed to show that patients who qualified for SRT therapy when given mavacamten. A number of them no longer qualified for SRT, no longer satisfied the requirements for that procedure given the effects seen once mavacamten was added. That is a good thing; however, SRT events were extremely few and evenly distributed across the groups; and because of that, we believe much of what was already understood regarding mavacamten got confirmed, so to speak, through VALOR. Regarding your specific question about how we are approaching this, I will have Fady weigh in. And you additionally raised the topic of the screen failure rate within Cohort 4. So Fady, could you please speak to those points?

Fady Malik

executive
#23

Absolutely. Hello, Yasmeen. Regarding the possibility that patients enrolled in SEQUOIA could play a role in securing a label expansion for reducing eligibility for SRT, we do have a plan in place. I'm not going to elaborate any further on that point. However, let me just point out that the patients who qualify for septal reduction therapy are those exhibiting Class 3/4 symptoms along with a high outflow tract gradient, which is also a prerequisite for entering SEQUOIA to begin with. Therefore, in my view, this is a group that could be regarded as SRT eligible, and that may help support a potential label for that specific therapeutic use. As for your other question about screen failures in Cohort 4, the rates of screen failure have not appeared to differ in any meaningful way — though I'd say they run a bit higher than what we observe among oHCM patients, partly due to the fact that one of the criteria for entering these studies involves a blood test, specifically NT-proBNP, and individuals don't always have a record of one when they undergo screening. Consequently, whether that blood test result establishes eligibility can go either way. Taking everything together, we've been quite satisfied with the activity in that study and with how patients have moved from screening into enrollment.

Yasmeen Rahimi

analyst
#24

Understood. Thanks, everyone. One final item. I really don't like being an analyst who claims to know the data, but it would be great to hear what you all think regarding your approach to a partnership for aficamten. Have your views on that shifted as you got closer to the close of the year, with enrollment updates picking up? Even a bit of color would be useful, then we can return to the Q.

Robert Blum

executive
#25

Absolutely; I'll handle that one. Our position remains the same; it is still our plan to retain aficamten for ourselves. We aim to move forward with commercialization of aficamten independently across North America and Europe. Although we've already struck a partnership for it in China, we are still looking for a collaborator in Japan — apart from that, we aren't actively seeking any partnership for aficamten.

Yasmeen Rahimi

analyst
#26

Thank you.

Robert Blum

executive
#27

Thank you.

Robert Blum

executive
#28

Hi there, Joe.

Joe Pantginis

analyst
#29

Hey, everyone. Good afternoon. Robert, regarding that new Philadelphia site of yours, I simply want to confirm everyone there is still on the job and hasn't gotten stuck watching the World Series. Having said that, I was hoping to ask…

Robert Blum

executive
#30

Sounds good, Joe, < >.

Joe Pantginis

analyst
#31

Right. My question concerns the dose-finding study you mentioned in connection with omecamtiv. Could you make clear whether this is something you might want to include in the initial label as part of your end-of-cycle talks, or might it instead be incorporated into clinical practice at a later point?

Robert Blum

executive
#32

That's a great question. As you're aware, an assay was used in GALACTIC-HF to make dose titration possible, aiming to bring patients into a target range for plasma concentration, and that assay performed quite effectively. In our opinion, it has value, so we'll do everything we can to ensure an assay could be on hand when omecamtiv mecarbil gains approval. Whether it ends up in the labeling is, I believe, ultimately something the FDA must decide, assuming the drug is approved. That's a topic we've been discussing with the FDA, and we'll be ready for whatever situation arises, hopefully, though we still lack genuine certainty on that point.

Joe Pantginis

analyst
#33

Understood. Understood. Then, turning to the ALS program and that open-label extension you mentioned, I realize it's still very early for that. But how much insight do you have when it comes to identifying patients for enrollment? For instance, are any prior tirasemtiv patients coming in yet, or is there potential to actually bring them in, as you suggested might be possible?

Robert Blum

executive
#34

I'm somewhat puzzled by that question. We're blinded in this study. COURAGE-ALS is a trial…

Fady Malik

executive
#35

Regarding the open-label extension — Joe, we have a couple of routes through which reldesemtiv gets supplied. That extension is available solely to those patients who finish COURAGE.

Joe Pantginis

analyst
#36

that involved the managed access program.

Fady Malik

executive
#37

the managed access program, precisely.

Joe Pantginis

analyst
#38

Yeah. Yeah, apologies for getting that name wrong. Yeah, that was my meaning, correct.

Robert Blum

executive
#39

That clears things up. I appreciate you clarifying that. So through the managed access program, we're looking at individuals who have exited our trials, and we'll be opening that managed access program to patients, including some who've taken tirasemtiv for 5 years. There are people who've been receiving tirasemtiv for more than 5 years, despite the fact that we halted any further work on tirasemtiv in 2017, and these patients are telling us they want to move over into the managed access program for reldesemtiv. So that choice will be on the table for them at some point later this year.

Joe Pantginis

analyst
#40

Understood. That's quite useful. Many thanks, everyone.

Robert Blum

executive
#41

Appreciate it.

Jason Butler

analyst
#42

Hi. Thanks.

Robert Blum

executive
#43

Hi, Jason.

Jason Butler

analyst
#44

Hello, Robert. I appreciate you fielding these questions. It's good to have the latest information about the commercial preparation for omecamtiv. Could you perhaps address a few of the things that are going to be gated after approval? And could you also share your current perspective regarding reimbursement, including the discussions that have already taken place, and how you're viewing the reimbursement environment for this drug? Thanks.

Robert Blum

executive
#45

Sure. I appreciate the question. I'll turn to Andrew Callos for the specifics, but as you've heard from us before and I'll say it again, over half — roughly two-thirds — of the expense we might anticipate being tied to launch and following launch is gated. And we're being extremely cautious and prudent regarding what we put money into at this point, mainly long lead time activities, since those would need to be ready in Q1 if this drug were able to launch during the first half of next year. That refers to internal home office-based staff who will handle a great deal of the planning efforts, plus certain sales managers — not all of them, as Andrew will explain — and I'll now have Andrew go into more detail.

Andrew Callos

executive
#46

Absolutely, Jason, and thanks for raising that. Regarding gating, we're putting in place items such as our sales reps, patient support initiatives, spending on media and advertising, meetings and events, along with speaker programs and speakers in our area — essentially anything operational, so to speak, once a product receives approval. Those costs make up most of the expenses for omecamtiv, as Robert mentioned. So we have strategies ready to carry out all of those activities, though none would happen unless approval comes through; that's when they'd take place. As for reimbursement and the reimbursement environment, as you're likely aware, the harsh solar market has — it contains more Medicare than any other channel from a payer standpoint, then commercial, and those Medicare and commercial payers are largely governed by a small number of PBMs on both sides. Such PBMs stand for health plans like Blue Cross Blue Shield and major health plans and employer groups. We've been engaging with regional payers such as Blue Cross Blue Shields, plus national payers like, say, United or CVS, Express Scripts. So, all the significant participants in the healthcare payer space. We've examined Cytokinetics. We have meeting plans to conduct actual more detailed clinical reviews. We're preparing submissions for reimbursement in Medicare with a number of players too. So we have a very strong access plan. Within the access team, the customer-facing access team, the ones who would call on these as customers were among our earliest hires, well over a year ago; so they've been out in the field a long while with their medical colleagues and engaging with these payers for quite some time now.

Jason Butler

analyst
#47

Great, and thanks for taking my question.

Robert Blum

executive
#48

Thank you, Jason.

Analyst

analyst
#49

Hello, Rob here, filling in for Madhu. Appreciate you fielding what we'd like to ask. I suppose what I really want to know is this: in what way are you approaching the subgroups within nonrestrictive HCM, plus heart failure with partial injection fraction, when it comes to afi?

Robert Blum

executive
#50

Of course. So, in what manner are we considering the groups of patients who, one would assume, stand a better chance of responding to a cardiac myosin inhibitor? Fady, would you like to handle that one?

Fady Malik

executive
#51

Okay. So, regarding NHCM, I'd say those cases are less common compared to individuals with OHCM. The goal should be to include as many people as possible instead of breaking them into smaller groups. At the same time, though, you need some objective indicator of the condition—something showing they're dealing with a meaningful pathophysiologic load tied to how far their disease has progressed. So, as with lots of studies, we'd want entry criteria tied to something measurable, like a possible biomarker that reflects filling pressures or general heart function, plus their capacity for exercise or symptoms. So, when considering how to split the population, my focus isn't really on ruling out particular NHCM subtypes, but rather on making sure we've got patients with symptoms who also have notable cardiac impairment. Then the second issue, in HFpEF, is that you're dealing with a far more varied group—ranging from ejection fractions of 55% and above, and including those with diabetes, obesity, and other conditions that might be driving their symptoms. So in that setting, I think we'd lean toward being more selective, trying to pinpoint characteristics within HFpEF that mark out a subgroup resembling our NHCM patients. And so, once again, without getting overly precise, that's the way we'd go about it.

Analyst

analyst
#52

Thank you.

Jeff Hung

analyst
#53

Thanks for taking my question. Regarding COURAGE-ALS, could you remind us what sets off the second interim analysis scheduled for next year? And then, I suppose, about possible changes to the study's size, can you discuss what the powering assumptions are for COURAGE-ALS, and also what factors would go into deciding whether the study size needs adjusting. Any insight you can offer would be appreciated. Thanks.

Robert Blum

executive
#54

Yes; so enrollment determines the trigger; once we reach roughly two-thirds of the planned enrollment, that sets off the second interim, with those patients having reached the same time point; as for the powering calculations and the possibility of upside, I'll have Fady address that please.

Fady Malik

executive
#55

Right. We haven't actually disclosed the particulars regarding the powering or the way that second interim analysis gets put together. A design paper is something we expect to publish, and it will contain a number of those specifics. Perhaps speaking broadly, though: my view is that the second interim serves 2 purposes. The first is a futility check, which lets the trial either keep going or move ahead, based on whether there's any possibility that the trial could show a positive effect. So if, at that interim analysis, the trial's odds of succeeding were really minimal, that would justify halting. On the sample size increase side, certain scenarios exist in which a positive effect appears to be present, yet we might lack sufficient power to pick up that effect with solid statistical confidence. In such a situation, the DMC is able to recommend that more patients be added to the trial, so that we'd have greater statistical power once the trial concludes. And there are also — some predefined boundaries exist around that, which we'll be able to say more about later on.

Robert Blum

executive
#56

I think that once that design paper comes out, you'll get more of your answers. But at the moment, that's the point where we feel comfortable with that disclosure.

Jeff Hung

analyst
#57

Thank you.

Robert Blum

executive
#58

Thank you, Jeff.

Robert Blum

executive
#59

Good afternoon.

Ash Verma

analyst
#60

Hello, and thank you, Robert, for allowing us to ask questions. There were a couple I wanted to raise. The first concerns Bristol's MYK-224. Perhaps you've come across this news. They are advancing it for obstructive HCM. Presumably its half-life is shorter and it carries no DDI, so a few of those same benefits that you've recognized at aficamten might be present over camzyos. Clearly, the clinical data will ultimately settle the matter, but at this point, how are you viewing the differences in profile between aficamten and MYK-224 based on what we currently know? The second one is about omecamtiv. So should your label end up with a PK-guided dosing strategy, in what way do you expect that to affect the commercial opportunity, if it does at all?

Robert Blum

executive
#61

So let's have Andrew address your second one, regarding how the addition of PK-guided dose titration could influence the commercialization. Then Fady can speak to your first one.

Andrew Callos

executive
#62

Absolutely. Appreciate the questions, Ash. Regarding PK at dosing — from the beginning, our plan and expectation was that PK-guided dosing would appear in the label, just as it did in our clinical trials. So as we see it and as we modeled it, no impact is anticipated; and in our conversations with cardiologists and clinicians, the patients — those with worsening heart failure — who might qualify as a suitable candidate for this therapy, undergo blood work routinely, for things like kidney function, blood sugar, and so on. And our expectation is that it's only needed for titration — to get started and to get the correct dose. So given those considerations, plus the fact that these kinds of tests happen frequently, we don't foresee any effect on how we commercialize the product.

Fady Malik

executive
#63

As for your question about MYK-224, Ash, I'm not in a position to say much, since no data from that compound has crossed my desk. Its properties, strictly speaking, are simply not something I have knowledge of. And making any remarks at this stage, I believe, would be premature on our part.

Robert Blum

executive
#64

I'd say that this compound has been on our radar for a very long while. MyoKardia would also describe it as something potentially carrying some advantageous characteristics. To me, this seems to confirm what could be a next-in-class profile for aficamten. And naturally, there are additional factors that set aficamten apart from mavacamten. But unless BMS produces data with 224, saying anything more would be premature.

Ash Verma

analyst
#65

Got it. Yeah, thank you.

Robert Blum

executive
#66

Thank you.

Salim Syed

analyst
#67

Thanks. Hello, everyone, and I appreciate your time for these questions. I have two, if that's all right. The first concerns omecamtiv, and the second involves aficamten. Robert, I realize you won't share a peak sales figure for omecamtiv, so let me try asking it another way. You gave us quite a bit of background on the spend today, and I'm grateful for that. What puzzles me slightly is this: does the spending gate hinge mainly on approval, is it an all-or-nothing matter tied to that, or does it depend more on how much demand the product actually sees? As a follow-up, could you help us frame how you think about the point when omecamtiv turns cash flow positive? Can you offer a range in years for when, in your view, omecamtiv reaches positive cash flow? Then, second, on aficamten, I'd like your perspective on the whole obstructive hypertrophic cardiomyopathy market following the Bristol announcement. They posted $5 million, clearly far under consensus. How does that shift your thinking on the peak total addressable market, and more specifically on the revenue opportunity for aficamten? Thank you.

Robert Blum

executive
#68

Certainly. Starting with omecamtiv mecarbil: our decision to put a gate on spending reflects our awareness that we must be careful about putting money into omecamtiv before it wins approval. Once approved, though, you should anticipate that we'll devote ourselves to what we think could be a highly effective commercial launch. As for whether other factors will shape how we dial spending up or down, it seems only reasonable that we'd consider market access and similar items as we raise spending to match that launch. Yet our plan, should the drug be approved, is to pursue it aggressively, as you'd expect for something capable of delivering the returns that you and other analysts have forecast. So, as you say, I won't discuss possible peak sales. Still, we believe this is a product that, commercialized by us in the United States, can yield positive net cash flows for the company. Regarding the timing, I'd say it resembles other new medicines in this class; we won't be turning a profit on the product during year one, yet we do anticipate strong performance, very strong, given the strategy Andrew and others are setting out and the clinical evidence they're building upon. As for how soon — whether that's year two, year three, or something like that — it hinges on pricing, and it hinges on market access. In certain regions, getting reimbursement will take longer, since the bulk of patients here fall under Medicare, and we must ensure those Medicare bids are properly handled; that is a process which requires time. Even so, you ought to anticipate that our view is this medicine does more than merely open a doorway for aficamten — once commercialized, we regard it as something capable of making a meaningful difference for the company and its shareholders. So that is likely the best answer I can give you today; when it comes to aficamten, allow me to state it plainly. Nothing about our expectations has shifted following the BMS print, even while I recognize that the sales figure disclosed for the latest quarter landed under the Wall Street consensus. My confidence remains full that BMS is taking the correct steps with the mavacamten launch; in their own remarks they have already noted how, during October, many patients were transitioning off free goods. Beyond that, there is the count of physicians trained via the REMS program who are able to serve as prescribers, how many keep prescribing, and how few, if any, are repeat prescribers who then fall away. BMS understands all of these dynamics extremely well and is constructing a commercial ramp for mavacamten exactly as we anticipated they would. Therefore, unless Andrew wishes to offer any remarks, I will close simply by saying that our belief stays very strong in the upside for mavacamten, and likewise, concerning aficamten, we hope and believe it could be a next-in-class compound. Andrew, is there anything more you would like to share regarding the mavacamten launch and what we are learning?

Andrew Callos

executive
#69

You handled that nicely. BMS brought up more than a thousand patients, and just one-third of those are commercial, as Robert mentioned. Still, from what claims data tells us, well over 190,000 patients already have a diagnosis, and likely three to four times as many remain undiagnosed. So this is a sizable market that has to be served, and building a market takes time. Therefore, as Robert pointed out — and BMS says the same — we hold a very bullish view on this market and on the chance for more than one company to succeed.

Salim Syed

analyst
#70

Great. Super helpful. Thanks so much, guys.

Andrew Callos

executive
#71

Sure.

Robert Blum

executive
#72

Hey there, Justin.

Justin Kim

analyst
#73

Hello, Robert, and hello to the rest of the team. Good afternoon, and I appreciate you taking my question. I'll keep it brief — it concerns the eligibility requirements for the second Phase 3 trial of aficamten going head-to-head against metoprolol. I'm just wondering if prior treatment exposure will factor into those criteria. Given the data on background withdrawal that came out not long ago, I'm curious about your thinking when it comes to testing this compound versus data blocker, and whether you might be considering randomized withdrawal, or more broadly how you'd approach washout of aficamton or datablocker over the course of this study?

Robert Blum

executive
#74

Right; well, you'll have your answer quite shortly, once this trial is designed and posted on clinicaltrials.gov, but perhaps Fady, if you'd be willing, could do whatever you can to address that.

Fady Ibraham

executive
#75

Justin, sure, that's a solid question. In this trial, the goal is to assign patients randomly to either a beta-blocker by itself or aficamten by itself, and you can accomplish that in a few different ways. One option is enrolling people who haven't started treatment yet and randomizing them. Alternatively, like you mentioned, it may be necessary to take patients off whatever therapy they're currently receiving, at minimum briefly, and then randomize them to one of the two active treatments. So we'll clarify more precisely what our approach will be; however, the majority of these patients — many of them, I should say, and I realize I said most but really it's many — are able to come off their background optimal therapy for a brief window and handle it fine.

Robert Blum

executive
#76

That is the pattern showing up in the open-label extension, and it is the reason so many investigators have been eager for us to run this trial.

Justin Kim

analyst
#77

All right, that's helpful. And perhaps only to clarify one point. Regarding the conclusion of the study, would it be reasonable to anticipate a washout of aficamten in this trial too?

Fady Ibraham

executive
#78

Well, when a study concludes, we typically include a washout phase, since checking whether the treatment effect reverses serves as another sign of how robust the effect was while on treatment. Therefore, I would anticipate that happening once the study ends.

Justin Kim

analyst
#79

Great. Thank you.

Robert Blum

executive
#80

Thank you.

Robert Blum

executive
#81

Hey there, Dane.

Dane Leone

analyst
#82

Hello. Alright, we are running nearly 10 minutes beyond the Amgen call at this point, so that itself is quite an accomplishment. One quick thing from me. If you folks have watched how Bayer and Merck launched Vericiguat, that seems like a situation worth drawing lessons from as you approach an approval for omecamtiv. So I suppose, what lessons stand out on your end regarding how one might handle a novel drug that would sit alongside guideline-directed therapy in patients already maxed out on that treatment? And, just to keep it truly simple for those of us who aren't the sharpest, is there any kind of red line when it comes to this AdCom and the labeling of omecamtiv where, going back to my point about Vericiguat capturing market share, you'd simply conclude it isn't worth pursuing, at least on your own in the US or Europe, something that would likely limit access? Thanks.

Robert Blum

executive
#83

Yeah. Those are good questions. Let me say that I've been examining the Vericiguat launch quite closely, and we hold very frequent meetings here where we review the data coming out of it. And it's quite revealing and instructive. And as you noted, competing against the pillars of standard of care is difficult. I won't say anything to disparage Vericiguat, but I do believe the profile of patients who'd gain benefit from omecamtiv once added to standard of care is quite distinct. And I do believe there are lessons to be drawn about how to communicate that via omnichannel marketing, via promotion. And the rep count, how they get deployed and positioned toward web centers — these are all things we're picking up on, some of which would resemble Vericiguat, while other things we'll do because it appears we can and perhaps they opted not to. It's a launch that benefits from, I suspect, the expectation that additional data will arrive. They're running, as you might know, a Phase 4 study. But the patient who might gain the most from omecamtiv is a higher-risk patient no matter how you assess risk — whether through ejection fraction, whether through blood pressure, potassium, recent hospitalization, BNP — any way you examine it, the greater the risk, the more likely patients are to benefit from omecamtiv once added to standard of care; and that works very much in our favor. I suppose there are scenarios in which it's conceivable the labeling would return so restrictive that it wouldn't be a launch we'd want to chase, but those aren't probabilistic scenarios given the conversations we're having; so we really don't have a line in the sand that would lead us to expect we wouldn't move forward if approved. To me, none of those situations are actual — they exist more as theoretical ideas. Andrew, is there anything you'd like to add?

Andrew Callos

executive
#84

Regarding the second item, what matters there as well, in my view, is our expectation that aficamten will reach the market several years following omecamtiv, and a significant expense category involving a costly field force — the very same field force. That, then, represents a cost-sharing component. As for the first item, I believe it truly comes down to four points. First, zeroing in on the appropriate patient category, positioning it clearly, and communicating that to doctors. Second, our concentration on cardiology along with heartfelt treatment centers. My sense is that we are allocating resources in a way that makes our focus on that extremely evident, along with patient support services and access. So while it is a challenging business, the formula itself is fairly straightforward; execution is simply difficult at times, and those four points are where our attention genuinely lies.

Dane Leone

analyst
#85

Thanks.

Charles Duncan

analyst
#86

Yeah. Hello. Robert and the rest of the team, congratulations on the advancement and best of luck with the AdCom that's coming up. My question was likely tied to the previous one, and it concerns the pluses and minuses of pharmacoeconomic worth for omecamtiv. I suppose what I'm curious about is, in terms of the benefit-risk assessment, which factor do you view as the crucial one that generates value for patients on omecamtiv, based on the data so far? And would you apply that same factor in Europe? Would it be appreciated over there too?

Robert Blum

executive
#87

Excellent questions. And indeed, in both the US and Europe, a compelling, quite convincing pharmacoeconomic value emerges once omecamtiv mecarbil is given alongside standard of care, and the outcome is fewer events; those events are chiefly heart failure hospitalizations in a population where being hospitalized is a major burden and where heart failure hospitalizations rank as the top cause of hospital admissions in the United States. So you're reaching, I think, the heart of where we truly see value, which explains why we believe we're encountering such enthusiasm from payers, particularly since this is a novel medicine that will be aimed at higher risk heart failure patients; they don't have to consider this for every one of their heart failure patients, but payers are seeking ways to keep people alive and out of the hospital; and that's precisely where omecamtiv appears to have its most marked effect in GALACTIC, above all for those patients considered at higher risk of hospitalization; so there's a strong, quite robust value story here that you've started to see us convey via analyses and presentations, and soon those will become publications that will inform potential use of omecamtiv mecarbil. So although quite often in these kinds of forums we discuss clinical safety and efficacy, I do think there's also a powerful economic and value case here, and that will be a central pillar of our messaging position.

Charles Duncan

analyst
#88

That's really useful. May I slip in one final item about reldesemtiv? I realize this call has covered a great deal. Quickly, though, regarding that second interim — I think you said enrollment sets it off. Yet my understanding is that it's set off once two-thirds have enrolled and been exposed for 12 weeks. Truly, is a 12-week period sufficient to determine if the drug could be showing activity that might translate into efficacy? What's your view on that?

Fady Malik

executive
#89

Hello, Charles. I'll have Stuart Kupfer take that one; and to be clear, are you referring to the first interim or the second interim?

Charles Duncan

analyst
#90

So I'd like to ask about the second interim. I'm aware of what the first interim looked like, but would this one be comparable?

Fady Malik

executive
#91

Regarding the first one — a third of the patients had reached 12 weeks. From that point, I'll hand it over to Stuart.

Stuart Kupfer

executive
#92

Hello, Charles. How are you doing? I appreciate you asking that. So, to make sure there's no confusion, the second interim analysis gets set off once a minimum of one-third of patients have completed 24 weeks of treatment. That analysis matters a great deal, since it roughly matches or lines up with the trial's primary endpoint — the change from baseline to ALS FRS at 24 weeks. As a result, the secondary announced will be more in line with what's expected for the primary endpoint. The first interim also served as a significant inflection point, given that it matched the treatment duration from the Phase II trial 4T2IALS < >; thus, it was a key benchmark for carrying out that futility analysis.

Charles Duncan

analyst
#93

Understood. That explanation is clear to me. I appreciate you letting me ask.

Stuart Kupfer

executive
#94

You're welcome.

Rohit Bhasin

analyst
#95

Good afternoon. Rohit here, sitting in for Serge. Appreciate you taking our questions. On omecamtiv — regarding the MAA submission in Europe, would you hold off until the AdCom result comes in and the PDUFA date is confirmed before you file? Then a second one on aficamten. With mavacamten now launched, has that changed awareness and interest when it comes to investigator and patient recruitment for SEQUOIA-HCM? Thanks.

Robert Blum

executive
#96

Sure. So on your first question, about filing an MAA in Europe for omecamtiv mecarbil, we view those as separate matters. The AdCom isn't really something we're looking at as a guide for when we intend to submit in Europe. As I said earlier, we've already had sufficient dialogue with FDA that we have a solid sense of what the AdCom will cover; the votes, naturally, we can't know, but we know enough about the way omecamtiv mecarbil will be discussed that we're already approaching our MAA with some understanding of FDA's thinking. And clearly, we've had our own interactions with EMA and Roper tours < >, so we get what the temperature is in Europe. So we'll move ahead. Obviously, once you've submitted and the filing is accepted, you get day 120 and other chances to engage with EMA, and it's possible that the AdCom vote and whatever PDUFA action occurs could shape how we handle a day 120 event — but not the submission itself. Your second question, about awareness of aficamten and SEQUOIA — is that correct?

Rohit Bhasin

analyst
#97

Yes. In what ways has mavacamten's launch affected awareness and interest when it comes to recruiting investigators and patients for SEQUOIA?

Robert Blum

executive
#98

Sure. I'll have Fady address that, please.

Fady Malik

executive
#99

Yeah. So I'd say, honestly, everyone in this space is pretty enthusiastic about cardiac myosin inhibitors as a way to treat this condition, and as far as enrollment for SEQUOIA goes, my impression is it hasn't taken a big hit, since that's something a few patients might look at, and it's a fairly solid choice, I'd say, because you can get open-label drug once the clinical trial wraps up. But the key thing is, this study isn't only running in the United States. It's also running in Europe. It's running in China, Israel. So right now, I'm certain there's been a bit of an effect, but my sense is it hasn't caused the trial to slow dramatically.

Rohit Bhasin

analyst
#100

Okay. Thank you.

Robert Blum

executive
#101

Thank you.

Robert Blum

executive
#102

Alright, thanks, operator. Given how lengthy this session has run, I'll keep it short. I'd simply like to express appreciation to everyone joining us on today's teleconference for your ongoing backing and curiosity about the work happening at Cytokinetics. Clearly, quite a bit is underway, with major events and milestones arriving in the near term — real momentum. Operator, that brings us to the point where we can wrap up the call now.

Operator

operator
#103

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.